Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Mersana Therapeutics, Inc. (MRSN)
|
Add to portfolio |
|
|
|
| Price: |
$16.16
| | Metrics |
| OS: |
120.5
|
M
| |
-240
|
% ROE
|
| Market cap: |
$1.95
|
B
| |
-197
|
% ROIC
|
|
Net cash:
|
$262
|
M
| |
$2.17
|
per share
|
|
EV:
|
$1.69
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($223)
|
M
| |
|
|
|
EBIT
|
($224)
|
M
| |
|
|
| EPS |
($2.08)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 26.6 | 0.0 | 0.8 | 42.1 | 10.6 | 17.5 | 0.0 | 10.4 |
| Revenue growth | 61716.3% | -94.8% | -98.0% | 297.6% | -39.6% | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 26.6 | 0.0 | 0.8 | 42.1 | 10.6 | 17.5 | 0.0 | 10.4 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | 100.0% |
| Research and development | 173.4 | 132.0 | 67.0 | 55.0 | 59.9 | 46.7 | 32.0 | 21.4 |
| General and administrative | 57.0 | 36.9 | 21.9 | 17.3 | 16.3 | 10.5 | 7.0 | 5.3 |
| EBIT | -203.3 | -167.7 | -88.1 | -32.2 | -67.1 | -40.5 | -13.9 | -16.3 |
| EBIT margin | -764.9% | -389990.7% | -10643.7% | -76.4% | -632.9% | -231.0% | | -157.7% |
| Pre-tax income | -204.2 | -170.1 | -88.0 | -28.2 | -64.3 | -38.7 | -13.7 | -16.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -204.2 | -170.1 | -88.0 | -28.2 | -64.3 | -38.7 | -13.7 | -16.4 |
| Net margin | -768.3% | -395488.4% | -10633.5% | -67.0% | -606.5% | -220.6% | | -158.6% |
| |
| Diluted EPS | ($2.18) | ($2.41) | ($1.43) | ($0.65) | ($2.79) | ($3.22) | ($10.82) | ($13.43) |
| Shares outstanding (diluted) | 93.7 | 70.6 | 61.5 | 43.5 | 23.0 | 12.0 | 1.3 | 1.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|